Supplementary Table 1: SLE patient demographic and clinical characteristics at baseline and follow-up for the entire lupus cohort

	Entire SLE cohort (N = 271)
Age at last visit, *median (Q1, Q3)*	43.1 (34.1, 53.3)
Age at enrolment, *median (Q1, Q3)*	37.4 (28.3, 49.4)
Disease duration at enrolment, *median (Q1, Q3)*	4.1 (1.0, 10.4)
No. clinic visits, *median (Q1, Q3)*	15 (7, 27)
Observation period (yrs), *median (Q1, Q3)*	3.9 (1.8, 6.8)
Female, *n (%)*	236 (87.1%)
Ethnicity	
Caucasian, *n (%)*	135 (55%)
Asian, *n (%)*	75 (30.7%)
Other, *n (%)*	34 (13.9%)
Medication use during observation period	
Prednisolone, *n (%)*	196 (72.3%)
Cumulative prednisolone (mg), *median (Q1, Q3)*	3809.8 (0.0, 10136.9)
TAM-prednisolone (mg/day), *median (Q1, Q3)*	3.3 (0.0, 7.6)
Hydroxychloroquine, *n (%)*	243 (98.8)
Other Immunosuppressants[#], *n (%)*	
Baseline SLEDAI-2K, median *(Q1, Q3)*	4.0 (2.0, 8.0)
AMS, median *(Q1, Q3)*	3.2 (1.7, 5.1)
LLDAS ever attained, *n (%)*	233 (86.6%)
LLDAS at last review, *n (%)*	135 (53.6%)
Organ damage (baseline) (SDI>0), *n (%)*	146 (53.9%)
Baseline SDI, *median (Q1, Q3)*	0.0 (0.0, 1.0)
Change in SDI >0, *n (%)*	101 (37.3%)

Data are n (%) or median (Q1, Q3). TAM-prednisolone= time-adjusted mean prednisolone.

AMS=time-adjusted mean Systemic Lupus Erythematosus Disease Activity Index 2000.

SDI=Systemic Lupus International Collaborating Clinics Damage Index. BMI=Body Mass

Index. #Methotrexate, azathioprine, mycophenolate mofetil, mycophenolic acid,

leflunomide, ciclosporin, cyclophosphamide, tacrolimus, rituximab or belimumab.